Clearside Biomedical Stock Discussion

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
Clearside Biomedical (NASDAQ: CLSD) showcased its suprachoroidal delivery technology and pipeline programs at multiple medical meetings across Asia, Europe, and the United States. The company made a significant impact at the 17th Asia-Pacific Vitreo-Retina Society Congress in Singapore with presentations on ODYSSEY topline resul...

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
Clearside Biomedical (CLSD) announced that its Asia-Pacific partner, Arctic Vision, has signed a commercial collaboration agreement with Santen Pharmaceutical for ARVN001 (branded as XIPERE® in the US) for treating uveitic macular edema in China. ...

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
Clearside Biomedical (Nasdaq: CLSD) presented positive data from its ODYSSEY Phase 2b trial for CLS-AX in wet AMD at the 2024 AAO Annual Meeting. The trial demonstrated extended duration and stable vision, with an 84% reduction in injection frequency after the initial dose. Approximately 90% o...

$Clearside Biomedical (CLSD.US)$ this stock will jump high mark this

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
Clearside Biomedical (Nasdaq: CLSD) announced positive topline results from its ODYSSEY Phase 2b trial of CLS-AX for treating wet AMD. The trial achieved all primary and secondary outcomes, demonstrating:
1. Stable visual acuity and anatomical control over 9 months
2. Positive safety profile with ...

$Clearside Biomedical (CLSD.US)$ For PM the buyers are strong right now anyways

$Clearside Biomedical (CLSD.US)$ Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
2 MINUTES AGO, 6:30 AM EDT
VIA GLOBENEWSWIRE
Maintained Stable Visual Acuity and Anatomical Control Over 9 Months -
- Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events -
- 67% of CLS-AX Participants Did Not Require Any Additional Treatment up to 6 Months -
- Redu...

$Clearside Biomedical (CLSD.US)$ ?